Newsbenzinga
Xeris Biopharma Holdings Raises FY2026 Sales Guidance from $380.000M-$390.000M to $385.000M-$390.000M vs $385.229M Est
· Published
Article summary
Please check the source for details.
An excerpt from the original article.Loading news article.
Comments —
Loading comments…